KBY Biotech Indexv0.0.34
Search
← Pipeline|Elralucimab

Elralucimab

Phase 2
AXS-7093
By Axsome
Source: Trial-derived·Trials: 2
Modality
Degrader
MOA
MDM2i
Target
CDK4/6
Pathway
Lipid Met
Heart FailureEpilepsy
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
~Apr 2019
→ ~Jul 2020
Phase 2
Oct 2020
→ Mar 2030
Phase 2Current
NCT05946995
834 pts·Heart Failure
2023-10→2030-03·Completed
NCT04708901
459 pts·Epilepsy
2020-10→2026-09·Completed
1,293 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-09-115mo awayPh2 Data· Epilepsy
2030-03-234.0y awayPh2 Data· Heart Failure
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2
Complet…
P2
Complet…
Catalysts
Ph2 Data
2026-09-11 · 5mo away
Epilepsy
Ph2 Data
2030-03-23 · 4.0y away
Heart Failure
Completed|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT05946995Phase 2Heart FailureCompleted834DAS28
NCT04708901Phase 2EpilepsyCompleted459CfB
Competitors (10)
DrugCompanyPhaseTargetMOA
DoxacapivasertibEli LillyPhase 3APOC3MDM2i
BMY-8678Bristol-Myers SquibbApprovedRETMDM2i
AMG-415AmgenPhase 1CDK2MDM2i
MotavorutinibAmgenPhase 3CDK4/6JAK1/2i
GIL-2037Gilead SciencesApprovedKRASG12DMDM2i
RibozanubrutinibRegeneronPhase 1CDK4/6IL-13i
MRN-5715ModernaNDA/BLACDK4/6AuroraAi
CapiglumideBioNTechPreclinicalCGRPMDM2i
RimasertibExelixisPhase 3B7-H3MDM2i
180-6098Innovent BioPhase 1ALKMDM2i